CONCORD BIOTECH
|
The Current P/E Ratio of CONCORD BIOTECH is 43.47.
| Share Price | ₹1,327.4 | Dec 22,2025 |
| Market Cap | ₹13,884.1 Cr | |
| Earnings-TTM | ₹319.4 Cr | TTM-Consolidated Results |
| Price/Earnings | 43.47x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of CONCORD BIOTECH
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹13,884.1 Cr] as on Dec 22,2025
(/) Earnings [ ₹319.4 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 43.47x ]
Thus, for CONCORD BIOTECH , the investors are currently willing to pay 43.47 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of CONCORD BIOTECH !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of CONCORD BIOTECH over the last five years.
Historical PE (Price/Earnings) ratio chart of CONCORD BIOTECH
PE Ratio Performance Analysis for CONCORD BIOTECH
- CONCORD BIOTECH 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 19.77x.
- CONCORD BIOTECH 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, CONCORD BIOTECH 's p/e ratio peaked in Mar2024 at 51.68x.
- CONCORD BIOTECH 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does CONCORD BIOTECH 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| CONCORD BIOTECH | 319.36 | 43.47 | 13,884.1 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 40.41 | 424,982.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 69.57 | 172,878.0 |
| CIPLA LTD | 5,453.86 | 22.40 | 122,175.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 60.32 | 129,095.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 18.73 | 107,154.0 |
| MANKIND PHARMA LTD | 1,767.06 | 51.10 | 90,303.2 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 18.58 | 92,392.4 |
| LUPIN LTD | 4,347.53 | 22.34 | 97,120.0 |
| AUROBINDO PHARMA LTD | 3,447.75 | 20.62 | 71,104.6 |
| ABBOTT INDIA LTD | 1,508.95 | 39.44 | 59,508.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs CONCORD BIOTECH 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.58x |
| Max industry PE | 69.57x |
| Median industry PE | 39.44x |
| Average industry PE | 37.00x |
You may also like the below Video Courses